DE60024967T2 - Chaperonin 10 und beta-interferon therapie für multiple sklerose - Google Patents

Chaperonin 10 und beta-interferon therapie für multiple sklerose Download PDF

Info

Publication number
DE60024967T2
DE60024967T2 DE60024967T DE60024967T DE60024967T2 DE 60024967 T2 DE60024967 T2 DE 60024967T2 DE 60024967 T DE60024967 T DE 60024967T DE 60024967 T DE60024967 T DE 60024967T DE 60024967 T2 DE60024967 T2 DE 60024967T2
Authority
DE
Germany
Prior art keywords
cpn10
ifn
day
treatment
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60024967T
Other languages
German (de)
English (en)
Other versions
DE60024967D1 (en
Inventor
Halle Coorparoo Brisbane MORTON
Alice Mitchelton Brisbane CAVANAGH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland
Original Assignee
University of Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland filed Critical University of Queensland
Application granted granted Critical
Publication of DE60024967D1 publication Critical patent/DE60024967D1/de
Publication of DE60024967T2 publication Critical patent/DE60024967T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Surgical Instruments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60024967T 1999-01-20 2000-01-20 Chaperonin 10 und beta-interferon therapie für multiple sklerose Expired - Lifetime DE60024967T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP823999 1999-01-20
AUPP8239A AUPP823999A0 (en) 1999-01-20 1999-01-20 A treatment
PCT/AU2000/000032 WO2000043033A1 (en) 1999-01-20 2000-01-20 CHAPERONIN 10 AND β-INTERFERON THERAPY OF MULTIPLE SCLEROSIS

Publications (2)

Publication Number Publication Date
DE60024967D1 DE60024967D1 (en) 2006-01-26
DE60024967T2 true DE60024967T2 (de) 2006-08-17

Family

ID=3812443

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60024967T Expired - Lifetime DE60024967T2 (de) 1999-01-20 2000-01-20 Chaperonin 10 und beta-interferon therapie für multiple sklerose

Country Status (12)

Country Link
US (1) US20090214473A1 (cg-RX-API-DMAC10.html)
EP (1) EP1150703B1 (cg-RX-API-DMAC10.html)
JP (1) JP4691257B2 (cg-RX-API-DMAC10.html)
KR (1) KR100694011B1 (cg-RX-API-DMAC10.html)
AT (1) ATE313332T1 (cg-RX-API-DMAC10.html)
AU (2) AUPP823999A0 (cg-RX-API-DMAC10.html)
CA (1) CA2361081C (cg-RX-API-DMAC10.html)
DE (1) DE60024967T2 (cg-RX-API-DMAC10.html)
DK (1) DK1150703T3 (cg-RX-API-DMAC10.html)
ES (1) ES2255484T3 (cg-RX-API-DMAC10.html)
PT (1) PT1150703E (cg-RX-API-DMAC10.html)
WO (1) WO2000043033A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517808A (ja) * 2004-01-16 2007-07-05 キュビオ リミテッド Ｔｏｌｌ様受容体誘導性のサイトカインおよびケモカイン分泌のシャペロニン１０調節
BG66458B1 (bg) * 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
EP2463307A1 (en) 2005-08-31 2012-06-13 CBIO Limited Modified chaperonin 10
CA2626692A1 (en) * 2005-10-20 2007-04-26 Cbio Limited Treatment of hypersensitivity
MX2008011167A (es) * 2006-03-02 2008-11-12 Cbio Ltd Regulaciòn de respuestas inmunes mediante la modulaciòn de la funciòn de cèlulas presentadoras de antìgenos.
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
US9359421B2 (en) 2008-04-08 2016-06-07 Tigo Gmbh Suppressor of the endogenous interferon-gamma
BG1430U1 (bg) * 2010-06-25 2011-04-29 Иван ИВАНОВ Фармацевтично средство
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015338A1 (en) * 1993-11-30 1995-06-08 The University Of Queensland Chaperonin 10
JPH10500109A (ja) * 1994-05-10 1998-01-06 イミユロジク・フアーマシユーチカル・コーポレーシヨン 多発性硬化症のための組成物および治療方法
DE19544768C1 (de) * 1995-11-30 1997-07-10 Rentschler Arzneimittel Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose

Also Published As

Publication number Publication date
CA2361081C (en) 2010-09-21
KR20020002376A (ko) 2002-01-09
EP1150703A1 (en) 2001-11-07
CA2361081A1 (en) 2000-07-27
KR100694011B1 (ko) 2007-03-12
AU2527100A (en) 2000-08-07
EP1150703A4 (en) 2004-11-10
ES2255484T3 (es) 2006-07-01
JP4691257B2 (ja) 2011-06-01
WO2000043033A1 (en) 2000-07-27
PT1150703E (pt) 2006-05-31
JP2002535286A (ja) 2002-10-22
US20090214473A1 (en) 2009-08-27
DE60024967D1 (en) 2006-01-26
DK1150703T3 (da) 2006-05-29
AU771867B2 (en) 2004-04-01
ATE313332T1 (de) 2006-01-15
EP1150703B1 (en) 2005-12-21
AUPP823999A0 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
DE69831971T2 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
DE69332518T2 (de) Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
DE69219782T2 (de) Verwendung eines thymosins bei der behandlung von hepatitis c
DE69621918T2 (de) Medikamente zur behandlung von autoimmunerkrankungen mit interferon-tau
DE69230862T2 (de) Rezeptoren zur Behandlung von Entzündungen vom verzögerten Typ
EP0203580B1 (de) Gamma-IFN als Wirkstoff zur Hemmung (Verhinderung) von Abbauprozessen im Knochen
US20090214473A1 (en) Combination chaperonin 10 and beta-interferon therapy for multiple sclerosis
DD241271A5 (de) Verfahren zur unterscheidung von normalen und boesartigen zellen in einer mischung in vitro
DE69331105T2 (de) Verwendung von thioureleyne und thiabendazol in auto immunbedingten und entzündlichen hauterkrankungen
EP0358130B1 (de) Mittel mit immunsuppressiver Wirkung
DE69812100T2 (de) Adenosin enthaltendes arzneimittel
DE60220894T2 (de) Verwendung von interleukin-12 zur behandlung von nervenschäden
DE69423806T2 (de) Therapeutisches Agens für NIDDM
DE69130679T2 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
DE69533311T2 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
DE69131202T2 (de) Die Verwendung von IL-4 und TNF zur Herstellung eines Medikaments zur Behandlung von Krebszellen
DE69029738T2 (de) Schutz gegen schock infolge einer schädigung durch doppelsträngige rna's
DE3780770T2 (de) Therapeutisches gemisch aus einem faenger von freien radikalen oder einem stoffwechsel-hemmer und einem biologisch aktiven protein.
DE69728654T2 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
DE69116552T2 (de) Verwendung von il-4 zur verstärkung der immunantwort auf infektiöse antigen-herausforderungen
RU2166959C2 (ru) Способ лечения аутоиммунных заболеваний с использованием интерферонов типа i
DE10120505A1 (de) Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von Krebserkrankungen
DE60125377T2 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
DE60209470T2 (de) Cd8alpha + lymphoid-dendritische zelle, die sich von einer humanen hämatopoetischen stammzelle unterscheidet, und differenzierungsverfahren dafür
DE60303296T2 (de) Verwendung von (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition